Articles published by Zealand Pharma
< Previous
1
2
Next >
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
August 22, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the First Half of 2024
August 15, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
August 12, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
July 29, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
June 25, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
June 25, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
June 25, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
June 20, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
June 06, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
May 31, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
May 29, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
May 23, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the First Quarter of 2024
May 16, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
May 09, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
March 01, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the Full Year 2023
February 27, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
February 20, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
January 19, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
January 17, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma completes registration of capital increase
January 12, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
January 10, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
January 08, 2024
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
January 02, 2024
From
Zealand Pharma
Via
GlobeNewswire
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
December 23, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
December 22, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
December 22, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
December 04, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
November 30, 2023
From
Zealand Pharma
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.